ATI Physical Therapy Receives Delisting Notice From the New York Stock Exchange

Rhea-AI Summary

ATI Physical Therapy (NYSE: ATIP) announced that its Class A common stock will be delisted from the New York Stock Exchange after market close on December 3, 2024, due to failing to maintain the required $15 million average global market capitalization over 30 consecutive trading days. The company's stock will transition to trading on the OTC Pink® Market.

ATI is currently in discussions for interim financing to provide liquidity opportunities for stockholders. The company states this transition won't affect its business operations, partner relationships, employees, or SEC reporting obligations. Management expressed confidence in their strategic plan and ongoing investments in people and patient experiences.

Positive

• Company is pursuing interim financing to provide stockholder liquidity
• Business operations, partnerships, and SEC reporting obligations remain unchanged

Negative

• Delisting from NYSE due to market cap falling below $15 million requirement
• Downgrade to OTC Pink® Market trading
• Company requires interim financing, indicating potential financial difficulties

Insights

Financial Analyst

The NYSE delisting of ATI Physical Therapy represents a significant negative development, highlighting severe financial distress. With a market cap of just $8.1 million, well below NYSE's $15 million minimum requirement, the company's transition to OTC Pink Market signals substantial deterioration in investor confidence and market value.

The company's pursuit of interim financing while claiming operational progress presents a concerning disconnect. This financing effort appears to be a last-ditch attempt to provide shareholders with an exit opportunity, suggesting potential preparation for more significant restructuring. The mention of a "simpler capital structure" often implies debt reorganization or potential bankruptcy preparations.

Trading on the OTC Pink Market will likely result in reduced liquidity, increased volatility and institutional investor participation. This downgrade in trading venue typically leads to decreased analyst coverage and harder access to capital markets, further compromising the company's financial flexibility.

Legal Expert

The delisting scenario presents significant compliance and disclosure obligations for ATI. While the company maintains its SEC reporting requirements, trading on the OTC Pink Market involves different regulatory oversight. Key legal considerations include:

The company must maintain careful disclosure practices during interim financing negotiations to avoid selective disclosure violations. The transition period requires meticulous securities law compliance, particularly regarding ongoing disclosure obligations and potential restructuring discussions.

Stockholders should anticipate potential securities litigation risks, as delisting events often trigger shareholder lawsuits. The company's statements about "delivering liquidity" and "simpler capital structure" warrant careful scrutiny for securities law implications and fiduciary duty considerations.

BOLINGBROOK, Ill., Dec. 3, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. (NYSE: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, today announced that it received notification from the New York Stock Exchange ("NYSE") indicating that the Company's Class A common stock will be delisted, and trading of its Class A common stock on the NYSE was suspended, after market close on December 3, 2024. The Company today also announced that it is currently in discussions to obtain interim financing in an effort to provide a near-term opportunity for the Company's common stockholders to obtain liquidity.

The Company anticipates that its Class A common stock will now begin trading publicly on the OTC Pink® Market. This transition to the over-the-counter market is not expected to affect the Company's business operations, its relationships with partners or employees, or its current Securities and Exchange Commission reporting obligations.

"Over the past year, we have made meaningful progress strengthening our operating performance and positioning the company for growth," said Sharon Vitti, Chief Executive Officer of ATI. "We remain confident in our strategic plan as we continue to invest in our people and deliver exceptional experiences for patients."

Joe Jordan, Chief Financial Officer of ATI, said, "The interim financing discussions we announced today are aligned to delivering liquidity to our stockholders while providing a possible path to a simpler capital structure."

The NYSE reached its decision to delist the Company's Class A common stock pursuant to Rule 802.01B of the NYSE Listed Company Manual, which requires listed companies to maintain an average global market capitalization of at least $15 million over a period of 30 consecutive trading days.

About ATI Physical Therapy

At ATI Physical Therapy, we are committed to making every life an active life. We provide convenient access to high-quality care to prevent and treat musculoskeletal (MSK) pain. Our 850+ locations in 24 states and virtual practice operate under one of the largest single-branded platforms built to support standardized clinical guidelines and operating processes. With outcomes from more than 3 million unique patient cases, ATI strives to utilize quality standards designed to deliver proven, predictable, and impactful patient outcomes. From preventative services in the workplace and athletic training support to outpatient clinical services and online physical therapy via our online platform, CONNECT™, a complete list of our service offerings can be found at ATIpt.com. ATI is based in Bolingbrook, Illinois.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the delisting of the Class A common stock from the NYSE and trading in the Class A common stock on the OTC Pink Open Market, and the impact on the Company's business operations. Forward-looking statements are based on the Company's current expectations and assumptions, which may not prove to be accurate. These statements are not guarantees and are subject to risks, uncertainties, and changes in circumstances that are difficult to predict, and significant contingencies, many of which are beyond the Company's control, that could cause actual results to differ materially and adversely from any of these forward-looking statements.

These forward-looking statements are subject to a number of risks and uncertainties, including the following:

• The Company's liquidity position raises substantial doubt about its ability to continue as a going concern;
• risks associated with liquidity and capital markets, including the Company's ability to generate sufficient cash flows, together with cash on hand, to run its business, cover liquidity and capital requirements and resolve substantial doubt about the Company's ability to continue as a going concern;
• the Company's ability to meet financial covenants as required by its 2022 Credit Agreement, as amended;
• risks related to outstanding indebtedness and preferred stock, rising interest rates and potential increases in borrowing costs, compliance with associated covenants and provisions and the potential need to seek additional or alternative debt or capital financing in the future;
• risks related to the Company's ability to access additional financing or alternative options when needed;
• the Company's dependence upon governmental and third-party private payors for reimbursement and that decreases in reimbursement rates, renegotiation or termination of payor contracts, billing disputes with third-party payors or unfavorable changes in payor, state and service mix may adversely affect the Company's financial results;
• federal and state governments' continued efforts to contain growth in Medicaid expenditures, which could adversely affect the Company's revenue and profitability;
• payments that the Company receives from Medicare and Medicaid being subject to potential retroactive reduction;
• changes in Medicare rules and guidelines and reimbursement or failure of the Company's clinics to maintain their Medicare certification and/or enrollment status;
• compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
• risks associated with public health crises, epidemics and pandemics, as was the case with the novel strain of COVID-19, and their direct and indirect impacts or lingering effects on the business, which could lead to a decline in visit volumes and referrals;
• the Company's inability to compete effectively in a competitive industry, subject to rapid technological change and cost inflation, including competition that could impact the effectiveness of the Company's strategies to improve patient referrals and the Company's ability to identify, recruit, hire and retain skilled physical therapists;
• the Company's inability to maintain high levels of service and patient satisfaction;
• risks associated with the locations of the Company's clinics, including the economies in which the Company operates and the potential need to close clinics and incur closure costs;
• the Company's dependence upon the cultivation and maintenance of relationships with customers, suppliers, physicians and other referral sources;
• the severity of climate change or the weather and natural disasters that can occur in the regions of the U.S. in which the Company operates, which could cause disruption to its business;
• risks associated with future acquisitions, divestitures and other business initiatives, which may use significant resources, may be unsuccessful and could expose the Company to unforeseen liabilities;
• risks associated with the Company's ability to secure renewals of current suppliers and other material agreements that the Company currently depends upon for business operations;
• failure of third-party vendors, including customer service, technical and information technology ("IT") support providers and other outsourced professional service providers to adequately address customers' requests and meet Company requirements;
• risks associated with the Company's reliance on IT infrastructure in critical areas of its operations including, but not limited to, cyber and other security threats;
• a security breach of the Company's IT systems or its third-party vendors' IT systems may subject the Company to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act;
• maintaining clients for which the Company performs management and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
• the Company's failure to maintain financial controls and processes over billing and collections or disputes with third-party private payors could have a significant negative impact on the Company's financial condition and results of operations;
• the Company's operations are subject to extensive regulation and macroeconomic uncertainty;
• the Company's ability to meet revenue and earnings expectations;
• risks associated with applicable state laws regarding fee-splitting and professional corporation laws;
• inspections, reviews, audits and investigations under federal and state government programs and third-party private payor contracts that could have adverse findings that may negatively affect the Company's business, including its results of operations, liquidity, financial condition and reputation;
• changes in or the Company's failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis;
• the Company's ability to maintain necessary insurance coverage at competitive rates;
• the outcome of any legal and regulatory matters, proceedings or investigations instituted against the Company or any of its directors or officers, and whether insurance coverage will be available and/or adequate to cover such matters or proceedings;
• general economic conditions, including but not limited to inflationary and recessionary periods;
• the Company's facilities face competition for experienced physical therapists and other clinical providers that may increase labor costs, result in elevated levels of contract labor and reduce profitability;
• risks associated with the Company's ability to attract and retain talented executives and employees amidst the impact of unfavorable labor market dynamics, wage inflation and recent reduction in value of the Company's share-based compensation incentives, including potential failure of steps being taken to reduce attrition of physical therapists and increase hiring of physical therapists;
• risks resulting from the 2L Notes, IPO Warrants, Earnout Shares and Vesting Shares being accounted for as liabilities at fair value and the changes in fair value affecting the Company's financial results;
• further impairments of goodwill and other intangible assets, which represent a significant portion of the Company's total assets, especially in view of the Company's recent market valuation;
• the Company's inability to maintain effective internal control over financial reporting;
• risks related to dilution of Class A common stock ownership interests and voting interests as a result of the issuance of 2L Notes and Series B Preferred Stock;
• costs related to operating as a public company; and
• the impact of the delisting of the Class A common stock from the NYSE.

If any of these risks materialize or the assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Investors should also review those factors discussed in the Company' Form 10-K and Form 10-Q for the fiscal year ended December 31, 2023, and quarter ended September 30, 2024, respectively, under the heading "Risk Factors," and other documents filed, or to be filed, by ATI with the SEC. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on the business of the Company or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligations to publicly update or revise any forward-looking statements after the date they are made or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or otherwise, except as required by law.

In addition, statements of belief and similar statements reflect the beliefs and opinions of the Company on the relevant subject. These statements are based upon information available to the Company, as applicable, as of the date of this communication, and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. 

Contacts

Investor Relations 
Scott Rundell 
VP, Finance and Head of Investor Relations 
ATI Physical Therapy 
investors@atipt.com 

Media Inquiries 
Michael Freitag / Aura Reinhard 
Joele Frank, Wilkinson Brimmer Katcher 
212-355-4449

Scott Parent 
Director of Communications 
ATI Physical Therapy 
scott.parent@atipt.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/ati-physical-therapy-receives-delisting-notice-from-the-new-york-stock-exchange-302321671.html

SOURCE ATI Physical Therapy

FAQ

Why is ATI Physical Therapy (ATIP) being delisted from NYSE?

ATI Physical Therapy is being delisted because it failed to maintain the NYSE requirement of a minimum $15 million average global market capitalization over 30 consecutive trading days.

Where will ATI Physical Therapy (ATIP) stock trade after NYSE delisting?

After delisting from NYSE, ATI Physical Therapy stock will trade on the OTC Pink® Market.

When will ATI Physical Therapy (ATIP) be delisted from NYSE?

ATI Physical Therapy will be delisted and trading suspended after market close on December 3, 2024.

What impact will the NYSE delisting have on ATI Physical Therapy's operations?

The company states the delisting will not affect its business operations, relationships with partners, employees, or SEC reporting obligations.